Unique immune cell structures in tumors can boost immunotherapy effects and enhance survival for patients with high-risk advanced melanoma, but testing is labor-intensive and not yet common. New AI-driven testing methods utilize low-cost and easily accessible technologies. They are designed to expedite testing, which could in turn facilitate physician-patient discussions on potential immunotherapy benefits.

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the mechanisms of action of tirzepatide – a drug known as Zepbound™ – on weight loss with respect to energy expenditure, fat oxidation and calorie intake. The study, “Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation,” published in Cell Metabolism, showed that tirzepatide decreased participants’ calorie intake at lunch/dinner by reducing appetite while increasing fat oxidation, thus helping participants to lose weight. However, the drug did not decrease the slowing down of their metabolic rate usually observed with weight loss.

 

MIT roboticists developed a way to cut through data noise and help robots focus on the features in a scene that are most relevant for assisting humans. The system could be used in smart manufacturing and warehouse settings where robots would work alongside and assist humans.

Mount Sinai-led research can transform how hospitals triage, risk-stratify, and counsel patients to save lives

The FAU Center for Connected Autonomy and Artificial Intelligence (CA-AI) has received a $799,759 grant from the U.S. Department of Defense to develop a state-of-the-art platform for testing and evaluating connected AI autonomous systems. The funding positions FAU as a national leader in this field and one of the first institutions to host a high-end NVIDIA GPU infrastructure for AI-driven autonomy research.